Mixed Connective Tissue Disease: Difference between revisions

No edit summary
No edit summary
Line 88: Line 88:
<br>  
<br>  


<sup></sup>Currently, there are three different criteria sets given by three authors: Modified Sharp et al (1987), Alarcon Segovia et al (1987), Kauskawa et al (1987).<ref name="U" />&nbsp;However, there is no standard or universal criteria set. There are currently three different criteria classification systems that are associated to predicting the probability that an individual may have MCTD. Listed below are the criteria sets that are presently used in the diagnosing MCTD.<br>  
<sup></sup>Currently, there are three different criteria classification systems that are associated with predicting the probability that an individual may have MCTD. These three classification systems are set forth by Modified Sharp et al (1987), Alarcon Segovia et al (1987), and Kauskawa et al (1987).<ref name="U" />&nbsp;Listed below are the criteria sets that are presently used in the diagnosing MCTD.<br>  


[[Image:Sharp01.png]]  
[[Image:Sharp01.png]]  

Revision as of 01:50, 11 April 2016

 

Welcome to PT 635 Pathophysiology of Complex Patient Problems This is a wiki created by and for the students in the School of Physical Therapy at Bellarmine University in Louisville KY. Please do not edit unless you are involved in this project, but please come back in the near future to check out new information!!

Definition/Description[edit | edit source]

Mixed connective tissue disease (MCTD) is a systemic disease which consists of clinical symptoms observed in the following three disorders: systemic lupus erythematosus, polymyositis, and systemic sclerosis.[1] [2] MCTD is considered an "overlapping disease" as it contains features of these three disorders. The features can be categorized broadly as arthritic changes, cardiopulmonary dysfunctions, skin changes, muscle weakness, kidney disease, and dysfunctions of the esophagus.[3]

The symptoms associated with the three underlying disorders do not generally present simultaneously.[4] It usually takes several years before the symptoms of each individual disorder present, which ultimately complicates the diagnosis of MCTD.[4] Typically, the first symptom to present is swelling of the fingers, or the presentation of “sausage fingers”.[5] As the disease progresses, it can often affect multiple organs such as the lungs, heart, and/or kidneys.[3] There is no cure for MCTD, however side effects can be managed through the use of medications.[5]



Prevalence[edit | edit source]

It has been reported that 80% of individuals diagnosed with MCTD are women, with the highest prevalence in the age group under thirty.[4] Other sources have reported statistics collected from patients ages 5 through 80, with the peak prevalence around 20 years of age. [6] It is estimated that this disease occurs in about 3.8 out of every 100,000 individuals. [2] 
 

Characteristics/Clinical Presentation [5][edit | edit source]

The initial sign of MCTD may be shown as a presentation of puffy and swollen hands, Raynaud’s phenomenon, and polyarthritis.[1][2][3][7][8]

Some of the classical conditions or "signs” of MCTD include:

 
Raynaud phenomenon
  • Inflammation of muscles and joints
  • Pulmonary hypertension
  • Raynaud phenomenon
  • Swollen fingers, often “sausage like”, can be a temporary stage of the disease, or may progress into limited movement of the fingers due to thinning of fingers and thickening of the skin[2]

The chart below lists some of the symptoms common versus uncommon symptoms in early stages of MCTD.[5]

Common.png

Associated Co-morbidities
[edit | edit source]

  • Pulmonary Hypertension [2][4][5]
  • Interstitial lung disease (20%) [4]
    End-stage interstitial lung disease
  • Heart disease [4]
  • Kidney damage (25%) [4]
  • Digestive tract damage [4], [7]
  • Anemia (75%) [4],[8],[9]
  • Necrosis [4]
  • Hearing loss [8][4][5][9]
  • Sjögren syndrome (25%)[2]

Medications
[edit | edit source]

  • Corticosteroids[4][6]
  • Anti-malarial drugs[4]
  • Calcium channel blockers[4]
  • Nonsteroidal anti-inflammatory drugs[2][6]
  • Immunosuppressive drugs[6]
  • Calcium channel blockers[2][4]
  • Phosphodiesterase inhibitors[2]
  • Endothelin receptor antagonists[2]
  • Prostoglandins[2]
  • Proton pump inhibitors[2]

Diagnostic Tests/Lab Tests/Lab Values[edit | edit source]

Laboratory Testing Often Includes:[2]

  • Anti-U1-RNP (rubonucleoprotein) antigens
  • Urinalysis
  • Muscle enzymes (myositis involvement)
  • Complete blood count (CBC)
  • Antinuclear antibodies
  • Lipase and amylase (pancreatitis involvement)
  • Routine blood chemistry

To check for systemic involvement, the following imaging testing can be performed[2]

  • Chest radiography- assesses for infiltrates, effusions, and cardiomegaly
  • MRI- asses for neuropsychiatric signs or symptoms
  • CT scan/ultrasound- evaluates abdominal pain in cases of suspected serositis, pancreatitis, and/or visceral perforation related to vasculitis
  • Echocardiography- assesses for effusion, chest pain, pulmonary hypertension, or valvular disease

Systemic involvement tests may also include cardiopulmonary testing, such as:[10]

  • Electrocardiography
  • Pulmonary function tests[11]
  • Six minute walk test [3]


Currently, there are three different criteria classification systems that are associated with predicting the probability that an individual may have MCTD. These three classification systems are set forth by Modified Sharp et al (1987), Alarcon Segovia et al (1987), and Kauskawa et al (1987).[9] Listed below are the criteria sets that are presently used in the diagnosing MCTD.

Sharp01.png

Alarcon-Segovia.png

Kauskawa.png

Etiology/Causes[edit | edit source]

The exact cause of MCTD is unknown, but it has been classified as an autoimmune disorder. Individuals with this disease have high levels of antinuclear antibodies (ANAs) and antibodies to U1 snRNP.[3] Due to the high number of autoimmune antigens in the body, the body will try to protect itself but instead attack healthy tissues.

MCTD has been linked to occur in individuals who report in having a family member who also has a connective tissue disease.[5] Also, certain exposures to chemicals or viruses such as silica or polyvinyl chloride have been found as potential causes of MCTD.[5]

Systemic Involvement[edit | edit source]

MCTD has a systemic component that has potentially drastic effects on many systems of the body including: 

Malar rash



SystemicInvolvement.png



Medical Management (current best evidence)[edit | edit source]

Since no cure has yet to be discovered for this disease, medical management is focused on treating the patient’s symptoms through the use of medication and minimizing systemic involvement. The symptoms of arthritis and/or arthralgia are often managed through the use of nonsteroidal anti-inflammatory drugs and hydroxychloroquine. Proton pump inhibitors are used to help control symptoms of esophageal reflux and calcium channel blockers are used in the treatment of Raynaud phenomenon. Low-dose corticosteroids and methotrexate are used in the treatment of synovitis and phosphodiesterase inhibitors, prostaglandins, and/or endothelin receptor antagonists are used to control pulmonary hypertension.[2]

The individual with MCTD should follow up with their physician in regard to screening for systemic involvement and depending on the impairments found, the patient should be referred to the appropriate specialist.

Physical Therapy Management (current best evidence)[edit | edit source]

Since there has been limited research regarding physical therapy treatment in patients with MCTD, interventions should be tailored to address the impairments of each individual. Although each person presents differently, there are some common areas that need to be addressed in all cases. Individuals with MCTD often present with decreased aerobic capacity and weakness of the proximal musculature.[10] Physical therapists should treat according to the common deficits seen in the disease as well as personal impairments that arise with each case.

Common areas of focus may include:

  • Educate patient regarding joint protection
  • Aerobic and endurance training
  • Range of motion exercises to maintain available range
  • Passive stretching, including splinting for joint protection
  • Strengthening total body exercises (including proximal musculature)
  • Skin education and management
  • Energy conservation techniques

Differential Diagnosis [2][edit | edit source]

  • Systemic Lupus Erythematosus- chronic inflammatory disease characterized by protean manifestations with a relapsing and remitting course
  • Scleroderma- progressive skin hardening and induration
  • Dermatomyositis- idiopathic inflammatory myopathy with characteristic signs commonly present in the skin, muscles, and joints
  • Polymyositis- idiopathic inflammatory myopathy which results in symmetrical proximal muscle weakness
  • Primary pulmonary hypertension- elevated pulmonary artery pressure with no known cause, if left untreated will lead to right-sided heart failure
  • Raynaud phenomenon- recurrent vasospasms of the fingers or toes which usually occurs as a result of stress or exposure to the cold
  • Bacterial sepsis- the presence of infection along with the systemic inflammatory response syndrome
  • Pleuritis- inflammation in the lining of the lungs
  • Rheumatoid arthritis- chronic systemic inflammatory disease with an unknown cause

Case Reports/ Case Studies[edit | edit source]

Karmacharya P, Mainali N, Aryal M, Lloyd B. Recurrent case of ibuprofen-induced aseptic meningitis in mixed connective tissue disease. Case Reports [Internet]. 2013 [2016 Apr 8];2013(apr30 1):bcr2013009571-bcr2013009571. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3645838/

Souto Filho J, de Barros P, da Silva A, Barbosa F, Ribas G. Thrombotic Thrombocytopenic Purpura Associated with Mixed Connective Tissue Disease: A Case Report. Case Reports in Medicine [Internet]. 2011 [Cited 2016 Apr 8];2011:1-5.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170900/

Fantò M, Salemi S, Socciarelli F, Bartolazzi A, Natale G, Casorelli I et al. A Case of Subacute Cutaneous Lupus Erythematosus in a Patient with Mixed Connective Tissue Disease: Successful Treatment with Plasmapheresis and Rituximab. Case Reports in Rheumatology [Internet]. 2013 [Cited 2016 Apr 8];2013:1-4. 

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3745888/

Resources
[edit | edit source]

About Mixed Connective Tissue Disease

www.mayoclinic.org/diseases-conditions/mixed-connective-tissue-disease/basics/definition/con-20026515

Help finding a rheumatologist
http://www.rheumatology.org/

Lupus Foundation of America, Inc.
[1]


Recent Related Research (from Pubmed)
[edit | edit source]

Failed to load RSS feed from http://www.ncbi.nlm.nih.gov/entrez/eutils/erss.cgi?rss_guid=18mpxdVb_vLku7kjdGuaFg9hju8HpipxsGa6yMB9xJAd2RTwR5|charset=UTF-8|short|max=10: Error parsing XML for RSS

References
[edit | edit source]

  1. 1.0 1.1 Fagundes MN, Caleiro MT, Navarro-rodriguez T, et al. Esophageal involvement and interstitial lung disease in mixed connective tissue disease. Respir Med [Internet]. 2009 [cited 2016 Mar 12];103(6):854-60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19201182
  2. 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 Mixed Connective-Tissue Disease: Background, Pathophysiology, Etiology [Internet]. Emedicine.medscape.com. 2016 [cited 8 April 2016]. Available from: http://emedicine.medscape.com/article/335815-overview
  3. 3.0 3.1 3.2 3.3 3.4 Mixed Connective Tissue Disease (MCTD) - NORD (National Organization for Rare Disorders) [Internet]. NORD (National Organization for Rare Disorders). 2016 [cited 8 April 2016]. Available from: http://rarediseases.org/rare-diseases/mixed-connective-tissue-disease-mctd/
  4. 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 Mixed connective tissue disease - Mayo Clinic [Internet]. Mayoclinic.org. 2016 [cited 2016 Apr 8]. Available from: http://www.mayoclinic.org/diseases-conditions/mixed-connective-tissue-disease/basics/definition/con-20026515
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Mixed Connective Tissue Disease [Internet]. My.clevelandclinic.org. 2016 [cited 2016 Apr 8]. Available from: https://my.clevelandclinic.org/health/diseases_conditions/hic_Mixed_Connective_Tissue_Disease
  6. 6.0 6.1 6.2 6.3 Mixed Connective Tissue Disease (MCTD) [Internet]. Merck Manuals Consumer Version. 2016 [cited 2016 Apr 8]. Available from: https://www.merckmanuals.com/home/bone,-joint,-and-muscle-disorders/autoimmune-disorders-of-connective-tissue/mixed-connective-tissue-disease-(mctd)
  7. 7.0 7.1 Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue disease. J Autoimmun [Internet]. 2014 [Cited 2016 Mar 12];48-49:46-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24461387
  8. 8.0 8.1 8.2 Cappelli S, Bellando randone S, Martinović D, et al. "To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum [Internet]. 2012 [cited 2016 Mar 12];41(4):589-98. Available from http://www.ncbi.nlm.nih.gov/pubmed/21959290
  9. 9.0 9.1 9.2 Ungprasert P, Wannarong T, Panichsillapakit T, et al. Cardiac involvement in mixed connective tissue disease: a systematic review. Int J Cardiol [Internet]. 2014 [Cited 2016 Mar 12];171(3):326-30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24433611
  10. 10.0 10.1 Van der net J, Wissink B, Van royen A, Helders PJ, Takken T. Aerobic capacity and muscle strength in juvenile-onset mixed connective tissue disease (MCTD). Scand J Rheumatol [Internet]. 2010 [Cited 2016 Mar 12];39(5):387-92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20604672
  11. Marigliano B, Soriano A, Margiotta D, Vadacca M, Afeltra A. Lung involvement in connective tissue diseases: a comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev [Internet]. 2013[Cited 2016 Mar 12];12(11):1076-84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23684699